Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Odense University Hospital
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05732389CT.gov Immunotherapy in Patients With Early dMMR Rectal Cancer | — | Recruiting | — | — | — |
NCT04751370CT.gov Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04362839CT.gov Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02948348CT.gov Study to Nivolumab Following Preoperative Chemoradiotherapy | — | Unknown | — | — | — |
NCT01769222CT.gov Ipilimumab and Local Radiation for Selected Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | Odense University Hospital | P2 | B · 63 |
| Irinotecan | Sun Yat-sen University | P4 | BBB |
| Fluorouracilum | Seoul National University Hospital | P3 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BBB |
| Capecitabine | Tao Zhang | P3 | BB |
| Cetuximab | Fudan University | P3 | BB |
| Indocyanine Green | National Cancer Center, China | P3 | BB |
| Floxuridine | City of Hope Medical Center | P2 | BB |
| Tipiracil | Academic and Community Cancer Research United | P2 | BB |
+42 more in the Rectal Cancer cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Rectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-rectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →